Latest Quarter
2025-10-31
KESTRA MEDICAL TECHNOLOGIES LTD (KMTS)
Revenue
$22.6M
Net Income
-$32.8M
Operating Margin
-140.7%
Free Cash Flow
-$101M
Debt / Assets
30.5%
Values are in USD and rounded to the nearest whole number unless noted.
Swipe horizontally to view all columns.
| Income Statement (Quarterly) | 2025-10-31 | 2025-07-31 | 2025-01-31 | 2024-04-30 |
|---|---|---|---|---|
| Revenue | 22,565,000 | 19,371,000 | 15,090,000 | 10,054,000 |
| Cost of Revenue | 11,141,000 | 10,520,000 | 8,543,000 | 8,657,000 |
| Gross Profit | 11,424,000 | 8,851,000 | 6,547,000 | 1,397,000 |
| Operating Expenses | ||||
| R&D Expenses | 0 | 0 | 0 | 0 |
| SG&A Expenses | 38,301,000 | 33,728,000 | 23,795,000 | 17,925,000 |
| Operating Expenses | 43,179,000 | 37,729,000 | 27,148,000 | 21,746,000 |
| Operating Income | -31,755,000 | -28,878,000 | -20,601,000 | -20,349,000 |
| Interest Expense | 1,901,000 | 1,912,000 | 1,783,000 | 1,935,000 |
| Income Before Tax | -32,751,000 | -25,793,000 | -21,741,000 | -22,311,000 |
| Income Tax Expense | 34,000 | 33,000 | 18,000 | -27,000 |
| Net Income | -32,785,000 | -25,826,000 | -21,509,000 | -22,284,000 |
| Per Share | ||||
| EPS | -0.64 | -0.50 | -0.50 | -0.45 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Statement (Annual) | 2025-04-30 | 2024-04-30 |
|---|---|---|
| Revenue | 59,815,000 | 27,814,000 |
| Cost of Revenue | 35,605,000 | 27,452,000 |
| Gross Profit | 24,210,000 | 362,000 |
| Operating Expenses | ||
| R&D Expenses | 0 | 0 |
| SG&A Expenses | 114,936,000 | 69,935,000 |
| Operating Expenses | 130,588,000 | 85,425,000 |
| Operating Income | -106,378,000 | -85,063,000 |
| Interest Expense | 7,734,000 | 6,230,000 |
| Income Before Tax | -113,679,000 | -94,096,000 |
| Income Tax Expense | 135,000 | 24,000 |
| Net Income | -113,814,000 | -94,120,000 |
| Per Share | ||
| EPS | -5.13 | -2.04 |
| EPS Diluted | 0.00 | 0.00 |
| Balance Sheet (Quarterly) | 2025-04-30 | 2024-04-30 |
|---|---|---|
| Assets | ||
| Cash and Cash Equivalents | 237,595,000 | 8,249,000 |
| Short Term Investments | 0 | 0 |
| Net Receivables | 8,081,000 | 1,998,000 |
| Inventory | 6,572,000 | 3,290,000 |
| Total Current Assets | 255,328,000 | 14,907,000 |
| Property Plant Equipment | 36,908,000 | 28,391,000 |
| Goodwill and Intangibles | 0 | 0 |
| Total Assets | 295,744,000 | 45,949,000 |
| Liabilities | ||
| Account Payables | 23,961,000 | 23,892,000 |
| Short Term Debt | 374,000 | 0 |
| Total Current Liabilities | 37,977,000 | 32,971,000 |
| Long Term Debt | 44,124,000 | 45,169,000 |
| Total Liabilities | 90,338,000 | 255,326,000 |
| Shareholders Equity | ||
| Retained Earnings | -520,249,000 | -406,435,000 |
| Total Shareholders Equity | 205,406,000 | -209,377,000 |
| Balance Sheet (Annual) | 2025-04-30 | 2024-04-30 |
|---|---|---|
| Assets | ||
| Cash and Cash Equivalents | 237,595,000 | 8,249,000 |
| Short Term Investments | 0 | 0 |
| Net Receivables | 8,081,000 | 1,998,000 |
| Inventory | 6,572,000 | 3,290,000 |
| Total Current Assets | 255,328,000 | 14,907,000 |
| Property Plant Equipment | 36,908,000 | 28,391,000 |
| Goodwill and Intangibles | 0 | 0 |
| Total Assets | 295,744,000 | 45,949,000 |
| Liabilities | ||
| Account Payables | 23,961,000 | 23,892,000 |
| Short Term Debt | 374,000 | 0 |
| Total Current Liabilities | 37,977,000 | 32,971,000 |
| Long Term Debt | 44,124,000 | 45,169,000 |
| Total Liabilities | 90,338,000 | 255,326,000 |
| Shareholders Equity | ||
| Retained Earnings | -520,249,000 | -406,435,000 |
| Total Shareholders Equity | 205,406,000 | -209,377,000 |
| Cash Flow Statement (Quarterly) | 2025-04-30 | 2024-04-30 |
|---|---|---|
| Operating Activities | ||
| Net Income | -113,814,000 | -94,120,000 |
| Depreciation & Amortization | 7,968,000 | 11,560,000 |
| Stock Based Compensation | 24,270,000 | 1,488,000 |
| Change in Working Capital | -6,203,000 | 4,388,000 |
| Operating Cash Flow | -77,608,000 | -72,235,000 |
| Investing Activities | ||
| Capital Expenditure | -23,591,000 | -12,514,000 |
| Investments | -23,591,000 | -12,514,000 |
| Investing Cash Flow | -23,308,000 | -12,229,000 |
| Financing Activities | ||
| Debt Repayment | 0 | 5,877,000 |
| Common Stock Issued/Repurchased | 215,789,000 | 0 |
| Dividends Paid | -1,654,000 | -799,000 |
| Financing Cash Flow | 330,262,000 | 77,725,000 |
| Summary | ||
| Free Cash Flow | -101,199,000 | -84,749,000 |
| Net Change in Cash | 229,346,000 | -6,739,000 |
| Cash Flow Statement (Annual) | 2025-04-30 | 2024-04-30 |
|---|---|---|
| Operating Activities | ||
| Net Income | -113,814,000 | -94,120,000 |
| Depreciation & Amortization | 7,968,000 | 11,560,000 |
| Stock Based Compensation | 24,270,000 | 1,488,000 |
| Change in Working Capital | -6,203,000 | 4,388,000 |
| Operating Cash Flow | -77,608,000 | -72,235,000 |
| Investing Activities | ||
| Capital Expenditure | -23,591,000 | -12,514,000 |
| Investments | -23,591,000 | -12,514,000 |
| Investing Cash Flow | -23,308,000 | -12,229,000 |
| Financing Activities | ||
| Debt Repayment | 0 | 5,877,000 |
| Common Stock Issued/Repurchased | 215,789,000 | 0 |
| Dividends Paid | -1,654,000 | -799,000 |
| Financing Cash Flow | 330,262,000 | 77,725,000 |
| Summary | ||
| Free Cash Flow | -101,199,000 | -84,749,000 |
| Net Change in Cash | 229,346,000 | -6,739,000 |